Advanced

Lipid-Lowering Therapy is Related to Inflammatory Markers and 3-Year Mortality in Patients With Critical Limb Ischemia.

Isma, Nazim LU ; Barani, Jamal LU ; Mattiason, Ingrid; Lindblad, Bengt LU and Gottsäter, Anders LU (2008) In Angiology 59. p.542-548
Abstract
To evaluate relationships between lipid-lowering therapy, inflammation, and 3-year mortality in critical limb ischemia (CLI), 259 consecutive CLI patients underwent evaluation of medication, tumor necrosis factor-alpha, interleukin-6 (IL6), neopterin, high-sensitivity C-reactive protein (hs-CRP), 8-epi-PGF2alpha, and endothelin-1. Mortality was assessed after 3 years. Sixty-one patients (24%) were on lipid-lowering therapy and 59 patients (97%) on statins. Patients on lipid-lowering therapy were younger and showed lower low-density lipoprotein cholesterol, hs-CRP, and IL-6 levels than patients without therapy. Three-year survival was higher among patients on lipid-lowering therapy. In logistic regression, the effect of lipid-lowering... (More)
To evaluate relationships between lipid-lowering therapy, inflammation, and 3-year mortality in critical limb ischemia (CLI), 259 consecutive CLI patients underwent evaluation of medication, tumor necrosis factor-alpha, interleukin-6 (IL6), neopterin, high-sensitivity C-reactive protein (hs-CRP), 8-epi-PGF2alpha, and endothelin-1. Mortality was assessed after 3 years. Sixty-one patients (24%) were on lipid-lowering therapy and 59 patients (97%) on statins. Patients on lipid-lowering therapy were younger and showed lower low-density lipoprotein cholesterol, hs-CRP, and IL-6 levels than patients without therapy. Three-year survival was higher among patients on lipid-lowering therapy. In logistic regression, the effect of lipid-lowering therapy on 3year survival was significant with inflammatory markers entered into the model one by one but disappeared when all inflammatory markers were entered into the model together. In conclusion, hs-CRP and IL-6 levels were lower and 3-year survival was higher in CLI patients on lipid-lowering therapy. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Angiology
volume
59
pages
542 - 548
publisher
SAGE Publications
external identifiers
  • WOS:000260483500003
  • PMID:18388063
  • Scopus:54049106192
ISSN
0003-3197
DOI
10.1177/0003319707306144
language
English
LU publication?
yes
id
0612ecdb-8010-4a9d-bb23-a80a972af0fa (old id 1147797)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/18388063?dopt=Abstract
date added to LUP
2008-05-09 09:02:19
date last changed
2016-11-13 04:30:16
@misc{0612ecdb-8010-4a9d-bb23-a80a972af0fa,
  abstract     = {To evaluate relationships between lipid-lowering therapy, inflammation, and 3-year mortality in critical limb ischemia (CLI), 259 consecutive CLI patients underwent evaluation of medication, tumor necrosis factor-alpha, interleukin-6 (IL6), neopterin, high-sensitivity C-reactive protein (hs-CRP), 8-epi-PGF2alpha, and endothelin-1. Mortality was assessed after 3 years. Sixty-one patients (24%) were on lipid-lowering therapy and 59 patients (97%) on statins. Patients on lipid-lowering therapy were younger and showed lower low-density lipoprotein cholesterol, hs-CRP, and IL-6 levels than patients without therapy. Three-year survival was higher among patients on lipid-lowering therapy. In logistic regression, the effect of lipid-lowering therapy on 3year survival was significant with inflammatory markers entered into the model one by one but disappeared when all inflammatory markers were entered into the model together. In conclusion, hs-CRP and IL-6 levels were lower and 3-year survival was higher in CLI patients on lipid-lowering therapy.},
  author       = {Isma, Nazim and Barani, Jamal and Mattiason, Ingrid and Lindblad, Bengt and Gottsäter, Anders},
  issn         = {0003-3197},
  language     = {eng},
  pages        = {542--548},
  publisher    = {ARRAY(0xc68cf18)},
  series       = {Angiology},
  title        = {Lipid-Lowering Therapy is Related to Inflammatory Markers and 3-Year Mortality in Patients With Critical Limb Ischemia.},
  url          = {http://dx.doi.org/10.1177/0003319707306144},
  volume       = {59},
  year         = {2008},
}